<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T16:05:42Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/181800" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/181800</identifier><datestamp>2025-11-20T15:00:27Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478916</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Gossypol Treatment Restores Insufficient Apoptotic Function of DFF40/CAD in Human Glioblastoma Cells</dc:title>
   <dc:creator>Martínez Escardó, Laura</dc:creator>
   <dc:creator>Alemany, Montse</dc:creator>
   <dc:creator>Sánchez Osuna, María</dc:creator>
   <dc:creator>Sánchez Chardi, Alejandro</dc:creator>
   <dc:creator>Roig Martínez, Meritxell</dc:creator>
   <dc:creator>Suárez García, Salvio</dc:creator>
   <dc:creator>Ruiz Molina, Daniel</dc:creator>
   <dc:creator>Vidal, Noemí</dc:creator>
   <dc:creator>Plans, Gerard</dc:creator>
   <dc:creator>Majós Torró, Carlos</dc:creator>
   <dc:creator>Ribas, Judit</dc:creator>
   <dc:creator>Baltrons, Maria Antonia</dc:creator>
   <dc:creator>Bayascas, Jose R.</dc:creator>
   <dc:creator>Barcia, Carlos</dc:creator>
   <dc:creator>Bruna, Jordi</dc:creator>
   <dc:creator>Yuste, Victor J.</dc:creator>
   <dc:subject>Apoptosi</dc:subject>
   <dc:subject>Tumors cerebrals</dc:subject>
   <dc:subject>Apoptosis</dc:subject>
   <dc:subject>Brain tumors</dc:subject>
   <dcterms:abstract>Glioblastoma (GBM) is a highly aggressive brain tumor and almost all patients die because of relapses. GBM-derived cells undergo cell death without nuclear fragmentation upon treatment with different apoptotic agents. Nuclear dismantling determines the point-of-no-return in the apoptotic process. DFF40/CAD is the main endonuclease implicated in apoptotic nuclear disassembly. To be properly activated, DFF40/CAD should reside in the cytosol. However, the endonuclease is poorly expressed in the cytosol and remains cumulated in the nucleus of GBM cells. Here, by employing commercial and non-commercial patient-derived GBM cells, we demonstrate that the natural terpenoid aldehyde gossypol prompts DFF40/CAD-dependent nuclear fragmentation. A comparative analysis between gossypol- and staurosporine-treated cells evidenced that levels of neither caspase activation nor DNA damage were correlated with the ability of each compound to induce nuclear fragmentation. Deconvoluted confocal images revealed that DFF40/CAD was almost completely excluded from the nucleus early after the staurosporine challenge. However, gossypol-treated cells maintained DFF40/CAD in the nucleus for longer times, shaping a ribbon-like structure piercing the nuclear fragments and building a network of bridged masses of compacted chromatin. Therefore, GBM cells can fragment their nuclei if treated with the adequate insult, making the cell death process irreversible.</dcterms:abstract>
   <dcterms:issued>2021-12-13T12:02:15Z</dcterms:issued>
   <dcterms:issued>2021-12-13T12:02:15Z</dcterms:issued>
   <dcterms:issued>2021-11-08</dcterms:issued>
   <dcterms:issued>2021-12-10T09:49:25Z</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:relation>Reproducció del document publicat a: https://doi.org/10.3390/cancers13215579</dc:relation>
   <dc:relation>Cancers, 2021, vol. 13, num. 21, p. 5579</dc:relation>
   <dc:relation>https://doi.org/10.3390/cancers13215579</dc:relation>
   <dc:rights>cc by (c) Martínez Escardó, Laura et al, 2021</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>MDPI AG</dc:publisher>
   <dc:source>Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>